Neurocrine biosciences, takeda announce collaboration to develop potential therapies for psychiatric disorders

Neurocrine biosciences and takeda announce collaboration to develop and commercialize potential therapies for psychiatric disorders.neurocrine biosciences - collaboration includes 3 clinical-stage assets with most advanced molecule in phase ii for negative symptoms of schizophrenia.neurocrine biosciences - takeda will receive $120 million in upfront cash.neurocrine biosciences- takeda will be entitled to development milestones of up to $495 million.neurocrine biosciences- takeda will be entitled to commercial milestones of up to $1.4 billion.neurocrine biosciences- takeda will be entitled to up to double-digit royalties on net sales.neurocrine biosciences- takeda retains ability to opt in or out of 50:50 profit share on all clinical programs at certain development events.neurocrine- agreement gives co exclusive worldwide rights to early-to-mid-stage psychiatry pipeline compounds within takeda's neuroscience portfolio.
NBIX Ratings Summary
NBIX Quant Ranking